Oric Pharmaceuticals, Inc. Financials
This page shows Oric Pharmaceuticals, Inc. (ORIC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Oric Pharmaceuticals, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Oric Pharmaceuticals, Inc. generates $0.88 in operating cash flow (-$112.7M OCF vs -$127.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Oric Pharmaceuticals, Inc.'s EBITDA was -$141.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 29.2% from the prior year.
Oric Pharmaceuticals, Inc. generated -$113.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 31.6% from the prior year.
Oric Pharmaceuticals, Inc. reported -$127.8M in net income in fiscal year 2024. This represents a decrease of 27.0% from the prior year.
Oric Pharmaceuticals, Inc. earned $-1.83 per diluted share (EPS) in fiscal year 2024. This represents an increase of 6.6% from the prior year.
Oric Pharmaceuticals, Inc. held $59.4M in cash against $0 in long-term debt as of fiscal year 2024.
Oric Pharmaceuticals, Inc. had 71M shares outstanding in fiscal year 2024. This represents an increase of 29.5% from the prior year.
Oric Pharmaceuticals, Inc. invested $114.1M in research and development in fiscal year 2024. This represents an increase of 33.9% from the prior year.
Oric Pharmaceuticals, Inc. invested $1.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 39.9% from the prior year.
ORIC Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $28.8M-5.8% | $30.5M+24.0% | $24.6M-21.0% | $31.2M+7.8% | $28.9M+31.8% | $22.0M | N/A | $22.4M |
| SG&A Expenses | $7.9M-7.2% | $8.5M+5.4% | $8.1M+13.5% | $7.1M+0.6% | $7.1M+0.7% | $7.0M | N/A | $6.3M |
| Operating Income | -$36.7M+6.1% | -$39.1M-19.4% | -$32.7M+14.6% | -$38.3M-6.4% | -$36.0M-24.2% | -$29.0M | N/A | -$28.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$32.6M+10.4% | -$36.4M-21.1% | -$30.0M+13.1% | -$34.6M-8.1% | -$32.0M-27.8% | -$25.0M | N/A | -$25.5M |
| EPS (Diluted) | $-0.33+29.8% | $-0.47-11.9% | $-0.42+14.3% | $-0.49-8.9% | $-0.45-21.6% | $-0.37 | N/A | $-0.44 |
ORIC Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $431.2M+24.3% | $346.9M+42.8% | $242.9M-11.4% | $274.1M-16.7% | $328.9M-6.2% | $350.8M+39.2% | $252.0M-8.1% | $274.3M |
| Current Assets | $295.6M+1.5% | $291.1M+37.7% | $211.4M-19.4% | $262.3M-11.0% | $294.6M-9.1% | $324.1M+52.4% | $212.6M-8.5% | $232.2M |
| Cash & Equivalents | $49.7M-34.5% | $75.9M+53.8% | $49.3M-17.0% | $59.4M+19.2% | $49.8M-11.6% | $56.4M+141.0% | $23.4M-10.9% | $26.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $24.3M+6.2% | $22.9M-1.1% | $23.1M-25.5% | $31.0M+17.0% | $26.5M+19.7% | $22.1M-20.7% | $27.9M+3.7% | $26.9M |
| Current Liabilities | $20.2M+11.8% | $18.1M+2.5% | $17.6M-29.1% | $24.8M+27.2% | $19.5M+28.5% | $15.2M-25.7% | $20.5M+8.0% | $18.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $406.9M+25.6% | $324.0M+47.4% | $219.7M-9.6% | $243.1M-19.6% | $302.4M-8.0% | $328.6M+46.7% | $224.1M-9.4% | $247.4M |
| Retained Earnings | -$661.7M-5.2% | -$629.1M-6.1% | -$592.8M-5.3% | -$562.8M-14.4% | -$491.9M-6.9% | -$459.9M-5.8% | -$434.9M-7.0% | -$406.6M |
ORIC Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$25.1M+18.6% | -$30.8M+5.2% | -$32.5M-16.0% | -$28.1M-9.5% | -$25.6M+15.1% | -$30.2M-24.4% | -$24.3M-23.5% | -$19.6M |
| Capital Expenditures | $35K-44.4% | $63K-83.7% | $387K+76.7% | $219K-34.2% | $333K+52.8% | $218K+282.5% | $57K-26.0% | $77K |
| Free Cash Flow | -$25.1M+18.6% | -$30.9M+6.1% | -$32.9M-16.4% | -$28.3M-8.9% | -$26.0M+14.6% | -$30.4M-25.0% | -$24.3M-23.3% | -$19.7M |
| Investing Cash Flow | -$110.5M-43.7% | -$76.9M-442.7% | $22.4M-47.4% | $42.7M+133.3% | $18.3M+129.5% | -$61.9M-395.1% | $21.0M+136.2% | -$57.8M |
| Financing Cash Flow | $109.5M-18.5% | $134.3M+1220827.3% | $11K-98.1% | $575K-29.5% | $816K-99.3% | $125.0M+27500.4% | $453K+1361.3% | $31K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ORIC Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -7.6%+2.9pp | -10.5%+1.9pp | -12.4%-0.9pp | -11.4%-1.7pp | -9.7%-2.6pp | -7.1% | N/A | -9.3% |
| Current Ratio | 14.65-1.5 | 16.13+4.1 | 12.00+1.4 | 10.55-4.5 | 15.08-6.2 | 21.31+10.9 | 10.39-1.9 | 12.26 |
| Debt-to-Equity | 0.06-0.0 | 0.07-0.0 | 0.11-0.0 | 0.13+0.0 | 0.09+0.0 | 0.07-0.1 | 0.12+0.0 | 0.11 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Oric Pharmaceuticals, Inc. profitable?
No, Oric Pharmaceuticals, Inc. (ORIC) reported a net income of -$127.8M in fiscal year 2024.
What is Oric Pharmaceuticals, Inc.'s earnings per share (EPS)?
Oric Pharmaceuticals, Inc. (ORIC) reported diluted earnings per share of $-1.83 for fiscal year 2024. This represents a 6.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Oric Pharmaceuticals, Inc.'s EBITDA?
Oric Pharmaceuticals, Inc. (ORIC) had EBITDA of -$141.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oric Pharmaceuticals, Inc.'s free cash flow?
Oric Pharmaceuticals, Inc. (ORIC) generated -$113.8M in free cash flow during fiscal year 2024. This represents a -31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oric Pharmaceuticals, Inc.'s operating cash flow?
Oric Pharmaceuticals, Inc. (ORIC) generated -$112.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Oric Pharmaceuticals, Inc.'s total assets?
Oric Pharmaceuticals, Inc. (ORIC) had $274.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Oric Pharmaceuticals, Inc.'s capital expenditures?
Oric Pharmaceuticals, Inc. (ORIC) invested $1.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Oric Pharmaceuticals, Inc. spend on research and development?
Oric Pharmaceuticals, Inc. (ORIC) invested $114.1M in research and development during fiscal year 2024.
How many shares does Oric Pharmaceuticals, Inc. have outstanding?
Oric Pharmaceuticals, Inc. (ORIC) had 71M shares outstanding as of fiscal year 2024.
What is Oric Pharmaceuticals, Inc.'s current ratio?
Oric Pharmaceuticals, Inc. (ORIC) had a current ratio of 10.55 as of fiscal year 2024, which is generally considered healthy.
What is Oric Pharmaceuticals, Inc.'s debt-to-equity ratio?
Oric Pharmaceuticals, Inc. (ORIC) had a debt-to-equity ratio of 0.13 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oric Pharmaceuticals, Inc.'s return on assets (ROA)?
Oric Pharmaceuticals, Inc. (ORIC) had a return on assets of -46.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Oric Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2024 data, Oric Pharmaceuticals, Inc. (ORIC) had $59.4M in cash against an annual operating cash burn of $112.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Oric Pharmaceuticals, Inc.'s Piotroski F-Score?
Oric Pharmaceuticals, Inc. (ORIC) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oric Pharmaceuticals, Inc.'s earnings high quality?
Oric Pharmaceuticals, Inc. (ORIC) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.